Westerkirk Capital Inc.

Position in NVO — Novo Nordisk A S

CIK 2080423 VICTORIA, A1

Position in NVO

as of Jun 30, 2026 · filed Aug 10, 2026 Compact

Position Value

$102,016

+$23,812 QoQ

Shares Held

2,128

0.0% QoQ

Ownership

0.000%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#1,068

of 1,348 holders

Holding Since

Sep 2025

4 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Westerkirk Capital Inc. holds $40,505,317 across 6 Drug Manufacturers - General names. NVO ranks #6 (0.3% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	LLY	ELI LILLY & Co	13,207	$15,840,873
2	JNJ	Johnson & Johnson	38,959	$9,894,417
3	MRK	Merck & Co., Inc.	46,500	$5,975,250
4	AZN	Astrazeneca PLC	28,729	$5,447,592
5	GILD	Gilead Sciences, Inc.	25,686	$3,245,169
6	NVO	Novo Nordisk A S This page	2,128	$102,016

4 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$102,016	2,128	0.0%	Shares	Sole	2026-08-10
2026-03-31	$78,204	2,128	0.0%	Shares	Sole	2026-05-14
2025-12-31	$108,272	2,128	-53.7%	Shares	Sole	2026-02-11
2025-09-30	$255,254	4,600	—	Shares	Sole	2025-11-10
No filing history on record for this holder in this stock.